-Live Mint Natco Pharma Ltd, which has started selling a generic version of Bayer AG’s patented cancer treatment Nexavar in India at a fraction of the price charged by the German firm, plans to use the so-called compulsory licensing route to try and win the right to copy more patented drugs, said vice-chairman and chief executive officer Rajeev Nannapaneni. The Hyderabad-based company has already identified the patented drugs for which it will...
More »SEARCH RESULT
The third gender's right to dignity-Prabha Sridevan
By recognising the rights of the transgender community, the state is not doling out largesse; it is only performing its duty under the Constitution They came beautifully dressed, some a tad brightly, but all beautifully and proudly, there was much chatter, and a lot of sisterhood. It was the public hearing of transgenders at Delhi. An excluded group must definitely feel cheered in a gathering, where the members of that group...
More »How PH Kurien took on global patents system to make very costly drug affordable for poor-Arvind Panagariya
It is said that only God and a few good men and women run India. One such man is P H Kurien. For readers unfamiliar with his name, Kurien was India's Controller General of Patents, Designs & Trade Marks until March 12, 2012. On March 9, 2012, just three days before he left office, he issued the first-ever compulsory licence in India for the manufacture of a drug still under patent....
More »India patent bypass delivers life-saving blow against cancer by Raja Murthy
India's decision this month to produce Germany-based multinational Bayer's anti-cancer drug Nexavar, in the first use of "compulsory licensing" in South Asia, will save lives but also raises intricate questions. Under the compulsory licensing process, a government can under World Trade Organization (WTO) rules bypass a patent owner's rights after three years and order the manufacture and sale of life-saving medicines at much cheaper cost than by obtaining the medicine from...
More »Govt uses special powers to slash cancer drug price by 97%-Rupali Mukherjee
In a landmark decision that could set a precedent on how life-saving drugs under patents can be made affordable, the government has allowed a domestic company, Natco Pharma, to manufacture a copycat version of Bayer's patented anti-cancer drug, Nexavar, bringing down its price by 97%. In the first-ever case of compulsory licencing approval, the Indian Patent Office on Monday cleared the application of Hyderabad's Natco Pharma to sell generic drug Nexavar,...
More »